

Electronic Acknowledgement Receipt

EFS ID:	3265748
Application Number:	10086294
International Application Number:	
Confirmation Number:	3210
Title of Invention:	Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
First Named Inventor/Applicant Name:	Loretta Nielsen
Customer Number:	20350
Filer:	Nathan S. Cassell/Cindy Keefe
Filer Authorized By:	Nathan S. Cassell
Attorney Docket Number:	016930-003712US
Receipt Date:	07-MAY-2008
Filing Date:	28-FEB-2002
Time Stamp:	12:18:22
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$ 180
RAM confirmation Number	6403
Deposit Account	201430
Authorized User	

File Listing:

Document Number	Document Description	File Name	File Size(Bytes) /Message Digest	Multi Part / .zip	Pages (if appl.)
-----------------	----------------------	-----------	-------------------------------------	-------------------	------------------

1	Foreign Reference	EP_0685493.pdf	405086 668ec7a8bbe6d3e4ec672abeb7b4a2e0 6ba0d013d	no	13
Warnings:					
Information:					
2	Foreign Reference	EP_0727486_A2.pdf	1197641 4963a299793ce333000a1a82650520011 11802667	no	32
Warnings:					
Information:					
3	Foreign Reference	WO_9406910.pdf	581604 99f1e6f8e523b4a30ca14860c97c05374 0ae63a395	no	18
Warnings:					
Information:					
4	Foreign Reference	WO_9505738.pdf	2501111 679ba78c1dea3a555c97a3421a5fab46 a961a7fc	no	65
Warnings:					
Information:					
5	Foreign Reference	WO_9511984.pdf	3617517 cc6413ec0647c1d1d48aa11cae9c00399 39c7997	no	93
Warnings:					
Information:					
6	Foreign Reference	WO_9621456.pdf	6416548 1a2a52a56de071850a42912991fa8ba2 267ec049	no	188
Warnings:					
Information:					
7	NPL Documents	ALBERTS_safety_aspects.pdf	816441 8782de4b7676a7e28ab3a09eae221800 efe9c066	no	7
Warnings:					
Information:					
8	NPL Documents	ALLAN_certoli_cell_death.pdf	1138074 118d0f064663939a7619aed05481e8497 69d3a70	no	11
Warnings:					
Information:					
9	NPL Documents	ALLEN_liposomes.pdf	992900 837e559e26726463623b5a0452a84f5b 89eca478a	no	8
Warnings:					
Information:					

10	NPL Documents	ANDERSON_human_gene_t herapy.pdf	1025556 8b6471a4b50d526c34160d15744c123 536a159	no	7
Warnings:					
Information:					
11	NPL Documents	BAXTER_cell_death.pdf	561942 4bdc24b8bb1bb4841e713b7efaae0a3be 9323ac3	no	8
Warnings:					
Information:					
12	NPL Documents	BLAGOSKLONNY_raf1_bc1 2_phosphorylation.pdf	966304 d3f1702d9f83a8e07ab3d482c174a20036 69a0bca0	no	6
Warnings:					
Information:					
13	NPL Documents	BLAGOSKLONNY_taxoI_ind uction.pdf	443933 b51e05d8dc239430590f03131e3ebf03 94f8f0c	no	4
Warnings:					
Information:					
14	NPL Documents	BULINSKI_overexpression.p df	1003740 0e653614bed017e23755397dcd596ee c05d6e6	no	11
Warnings:					
Information:					
15	NPL Documents	CHEN_genetic_mechanisms .pdf	632332 97d69b1ebc7443911f5534ab73695356 4a0e65ae	no	6
Warnings:					
Information:					
16	NPL Documents	CLARKE_thymocyte_apopto sis_induced.pdf	405596 221704f351ee07041b47d0d9978d1b16 5a9171ec	no	4
Warnings:					
Information:					
17	NPL Documents	CLAYMAN_adenovirus_med iated.pdf	1088166 c1b099dbd11f95c1a321d9b47716d1654 3ba150b	no	13
Warnings:					
Information:					
18	NPL Documents	COLUMBANA_occurrence_o f_cell_death.pdf	653949 1ed950894044e0c05da9910c06575879 9a9f9a0a	no	7
Warnings:					
Information:					

19	NPL Documents	DASS_enhanced_anticaner.pdf	350255 24240d967426b2c361dca766c4b2b2eb1ec7a	no	4
Warnings:					
Information:					
20	NPL Documents	DENNING_bystander_effects.pdf	844577 4479eb0105c66c9b45d559b88e0a3ab67c5114c	no	12
Warnings:					
Information:					
21	NPL Documents	DONEHOWER_the_cancer_bulletin.pdf	646267 d05c8a779f93611ac977a295a57c8b9c346b234	no	7
Warnings:					
Information:					
22	NPL Documents	DRAZAN_in_vivo.pdf	935362 a7540fec0052f347a784c392f0c41f7f6b18ac7f	no	9
Warnings:					
Information:					
23	NPL Documents	FUJIWARA_gene_therapeutics_and_gene_therapy.pdf	918087 9638e0e553cdamb696143d19429a828ba8b0a3	no	10
Warnings:					
Information:					
24	NPL Documents	GOBE_cell_death_by_apoptosis.pdf	939763 8907b9263b1000253a3ca9f1866a52ec6202dfe66	no	11
Warnings:					
Information:					
25	NPL Documents	IJIR_Aptosis_cell_death_induced.pdf	473827 0030619ab93d57b655a512ba3614c39fba4c05d	no	6
Warnings:					
Information:					
26	NPL Documents	IJIRI_cell_death_Aptosis_in_mouse.pdf	821293 402998b27b672e6a46b403173305a6d9771791	no	13
Warnings:					
Information:					
27	NPL Documents	IWADATE_mutation_of_the_p53_gene.pdf	326862 e62f8ba349c058164d97b0c9d9c9d3cc6264f06	no	5
Warnings:					
Information:					

28	NPL Documents	KIANMANESH_a_distant_by stander.pdf	760270 f32a44ed3108c52784ce83ae461aa44 dd84ef4	no	9
Warnings:					
Information:					
29	NPL Documents	LANNI_p53_independent_ap optosis.pdf	584093 838e6da96189e995a36c97e18e2301e4 1c08a3e1	no	6
Warnings:					
Information:					
30	NPL Documents	LECHANTEUR_hsv_1_thymi dine.pdf	551849 e1c9d801e0f77c9973da93b7e0d91b5aa4 11c09885	no	7
Warnings:					
Information:					
31	NPL Documents	LIU_growth_suppression.pdf	576771 a3fde1e43f86e5b0a5005766251f93 32b7313	no	7
Warnings:					
Information:					
32	NPL Documents	LOPES_assessment_of_mic rotubule.pdf	366096 1c85e068033539128ac05b3508e676 ea85185a	no	6
Warnings:					
Information:					
33	NPL Documents	LOWE_p53_dependent.pdf	970406 884c733a5d35b3772b2915d3bd2f89d 2673e1a2	no	12
Warnings:					
Information:					
34	NPL Documents	MALLAMS_antitumor_8.pdf	656454 1539c56bb2118608e1199b866ba3c06 d3974416	no	8
Warnings:					
Information:					
35	NPL Documents	MUHLRADT_epothilone_B stabilizes.pdf	248543 71378ka21eaff8cd39c9c06e091728f5952 d38b571	no	3
Warnings:					
Information:					
36	NPL Documents	NIELSEN_and_MANEVAL_p 53_tumor_suppressor.pdf	1106260 4616eb3da4ad35a31b770861f50112ca 4659741e05	no	13
Warnings:					
Information:					

37	NPL Documents	NIKIFOROV_suppression_of_apoptosis.pdf	478223 b7731ad8ff514e60c9ff8b935d110a1d35534	no	6
Warnings:					
Information:					
38	NPL Documents	NJOROGE_structure_activy.pdf	1270443 73d7602e0425a7a2a3a1669558b91c43d4b3b58	no	13
Warnings:					
Information:					
39	NPL Documents	ONO_regression.pdf	922026 02bcbf7265c4b67633cae677313ab34c541db17b2	no	14
Warnings:					
Information:					
40	NPL Documents	ORKIN_and_MOTULSKY_report_and_recommendations.pdf	1397133 d455d2d8bb143c971b0c89f0120c0ced126967057	no	21
Warnings:					
Information:					
41	NPL Documents	PANDA_differential_effects.pdf	664471 3f25ed25ea29388c11c019ab2e32ae05871e5386	no	7
Warnings:					
Information:					
42	NPL Documents	PANDA_stabilization_of_microtubules.pdf	599244 b9dfb63f623614169368b30337a01b93026ceb	no	6
Warnings:					
Information:					
43	NPL Documents	QAZILBASH_cancer_gene_therapy.pdf	713018 679a042cc0bd0dabe5cae61e613ab7f9c0a0cc5ed	no	8
Warnings:					
Information:					
44	NPL Documents	RABINOVITCH_combination_therapy.pdf	728643 8110656b7563d4bc8928822d3d7f86372a9a93e4	no	7
Warnings:					
Information:					
45	NPL Documents	REID_intravascular_adenoviral_agents.pdf	765684 302bce9f6b661643320b0304166c4db37be7865	no	8
Warnings:					
Information:					

46	NPL Documents	ROTH_modification_of_tumor_suppressor_gene.pdf	1357766 8eae3cc90610e29947efe237e39c0b295cc0f182d	no	16
Warnings:					
Information:					
47	NPL Documents	ROTH_Proc_Am_Association_Cancer_research.pdf	316195 3dc0d929f3a32047e644d8b1ee68d02e3405f33d5	no	3
Warnings:					
Information:					
48	NPL Documents	SARRAF_kinetic_studies.pdf	811052 192f7c08b6f956d12cb299b30c3f0c081da061d	no	11
Warnings:					
Information:					
49	NPL Documents	SCHULER_a_phase_I_study.pdf	624967 295e0d2d0c377ab0a0b1914133f0ea2eab57a73b	no	8
Warnings:					
Information:					
50	NPL Documents	SETH_a_recombinant_adenovirus.pdf	793920 53aa524dbcb9a4ac5c59a949e732e4db64ba765e	no	10
Warnings:					
Information:					
51	NPL Documents	SHAW_induction.pdf	510299 83b0e0ef542b6c56d14a87002578b8d0ca15e6	no	5
Warnings:					
Information:					
52	NPL Documents	SU_tissue_specific_expression.pdf	551186 63bead98a72916495c8a007735f5dabb0bba1e3	no	7
Warnings:					
Information:					
53		3rd_SIDS_016930_003712US_61358315_1.pdf	306227 67a2a8654669a2a1ba5db93d619ac0580b3b73	yes	9
	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Information Disclosure Statement Letter		1	2	
	Information Disclosure Statement (IDS) Filed		3	9	

Warnings:					
Information:					
54	NPL Documents	SUN_ras_caax_peptidomimetic.pdf	523644 bac3eaf0a9a3697d1225a71acbf9b1c80034a9	no	5
Warnings:					
Information:					
55	NPL Documents	VASQUEZ_nanomolar.pdf	1228862 60c674c9567c1db5c42bb033da336150240907a0	no	14
Warnings:					
Information:					
56	NPL Documents	WAHL_loss_of_normal_p53.pdf	820718 06c4a2bdf6b6a3e156349f05d5110f1784911cb0b	no	8
Warnings:					
Information:					
57	NPL Documents	WEEDON_apoptosis.pdf	1595867 2b4da704e9b9a3920c02a7314299d7242c50612c0	no	13
Warnings:					
Information:					
58	NPL Documents	WIZNEROWICZ_double_copoly.pdf	837047 827ac051a7ac9137bd3c120ac8f6e14db613967b7	no	8
Warnings:					
Information:					
59	NPL Documents	YEAGER_overcoming_cellular_senescence.pdf	1063797 03456dc6430791c354fab7b7b5b4591e44e63e63f	no	12
Warnings:					
Information:					
60	Fee Worksheet (PTO-06)	fee-info.pdf	8211 4b66ae2a475650e6c268484dbdb38cae32e8b7ef	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			55414118		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.